CNBX Pharms Financials
This page shows CNBX Pharms (CNBX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 21 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
CNBX Pharms passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, CNBX Pharms generates $0.55 in operating cash flow (-$171K OCF vs -$314K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
CNBX Pharms earns $-5.9 in operating income for every $1 of interest expense (-$272K vs $46K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
CNBX Pharms generated $0 in revenue in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
CNBX Pharms's EBITDA was -$272K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 46.8% from the prior year.
CNBX Pharms reported -$314K in net income in fiscal year 2025. This represents an increase of 54.8% from the prior year.
CNBX Pharms earned $0.00 per diluted share (EPS) in fiscal year 2025. This represents an increase of 100.0% from the prior year.
CNBX Pharms held $15K in cash against $0 in long-term debt as of fiscal year 2025.
CNBX Pharms had 554M shares outstanding in fiscal year 2025. This represents an increase of 1680.6% from the prior year.
CNBX Pharms invested $0 in research and development in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
CNBX Income Statement
| Metric | Q1'26 | Q1'25 | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | N/A | $0 | $0 | $0-100.0% | $2K | $0-100.0% | $41K |
| Cost of Revenue | N/A | N/A | N/A | $0 | N/A | N/A | N/A | $6K |
| Gross Profit | N/A | N/A | N/A | $0 | N/A | N/A | N/A | $34K |
| R&D Expenses | $0 | N/A | $0 | $0 | $0-100.0% | $478K+1014.1% | $43K-60.0% | $107K |
| SG&A Expenses | $64K | N/A | $40K-37.6% | $65K+75.8% | $37K-86.7% | $277K+153.7% | $109K-18.1% | $134K |
| Operating Income | -$64K | N/A | -$40K+37.6% | -$65K-75.8% | -$37K+96.2% | -$980K-543.4% | -$152K+26.2% | -$206K |
| Interest Expense | $46K | N/A | $16-55.6% | $36-98.8% | $3K | N/A | $62+663.6% | -$11 |
| Income Tax | $0 | N/A | $0 | $0 | $0 | N/A | $0 | N/A |
| Net Income | -$114K | N/A | -$60K+14.4% | -$70K-103.2% | -$34K+97.5% | -$1.4M-966.6% | -$131K+59.9% | -$325K |
| EPS (Diluted) | $0.00 | N/A | $0.00 | $0.00 | $-0.00 | N/A | $0.00+100.0% | $-0.01 |
CNBX Balance Sheet
| Metric | Q1'26 | Q1'25 | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $11K-39.5% | $18K-1.0% | $19K-63.3% | $51K+127.1% | $22K-28.9% | $31K-60.8% | $80K-51.2% | $164K |
| Current Assets | $11K-39.5% | $18K-1.0% | $19K-63.3% | $51K+127.1% | $22K-28.9% | $31K-60.8% | $80K-51.2% | $164K |
| Cash & Equivalents | $8K-49.0% | $15K+10.7% | $14K-70.1% | $46K+163.4% | $17K-34.4% | $26K-64.0% | $73K+97.6% | $37K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $2.6M+2.8% | $2.5M-1.6% | $2.6M-2.5% | $2.6M+3.3% | $2.5M+1.0% | $2.5M-0.9% | $2.5M+0.5% | $2.5M |
| Current Liabilities | $2.6M+2.8% | $2.5M-1.6% | $2.6M-2.5% | $2.6M+3.3% | $2.5M+1.0% | $2.5M-0.9% | $2.5M+0.5% | $2.5M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$2.6M-3.1% | -$2.5M+1.6% | -$2.5M+1.3% | -$2.6M-2.2% | -$2.5M-1.4% | -$2.5M-1.0% | -$2.5M-4.1% | -$2.4M |
| Retained Earnings | -$25.4M-0.5% | -$25.3M-0.6% | -$25.1M-0.2% | -$25.1M-0.3% | -$25.0M-0.1% | -$25.0M-0.2% | -$24.9M-0.5% | -$24.8M |
CNBX Cash Flow Statement
| Metric | Q1'26 | Q1'25 | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$47K-66.1% | -$29K+45.1% | -$52K-0.7% | -$52K-32.2% | -$39K+19.0% | -$48K-21544.4% | $225+100.2% | -$124K |
| Capital Expenditures | $4K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | -$113K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $0 | $0 | $0 | $0 | $0 | $0-100.0% | $95K+373.4% | $20K |
| Financing Cash Flow | $40K+33.3% | $30K+50.1% | $20K-75.0% | $80K+166.7% | $30K+2281.0% | $1K+0.1% | $1K | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CNBX Financial Ratios
| Metric | Q1'26 | Q1'25 | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 84.7% |
| Operating Margin | N/A | N/A | N/A | N/A | -46514.0%+1092.8pp | -47606.8%-11517.8pp | -36089.0%-35581.0pp | -508.0% |
| Net Margin | N/A | N/A | N/A | N/A | -293169.6%-225469.3pp | -67700.3%-42355.4pp | -25344.9%-24544.0pp | -800.9% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 20.8% |
| Return on Assets | -1018.8% | N/A | -320.8%-183.1pp | -137.8%+16.2pp | -154.0%-144.8pp | -9.2%+154.1pp | -163.2%+35.3pp | -198.6% |
| Current Ratio | 0.000.0 | 0.010.0 | 0.01-0.0 | 0.02+0.0 | 0.010.0 | 0.01-0.0 | 0.03-0.0 | 0.07 |
| Debt-to-Equity | -1.000.0 | -1.010.0 | -1.01+0.0 | -1.02-0.0 | -1.010.0 | -1.01+0.0 | -1.03+0.0 | -1.07 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$2.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.01), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is CNBX Pharms's annual revenue?
CNBX Pharms (CNBX) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is CNBX Pharms's revenue growing?
CNBX Pharms (CNBX) revenue declined by 100% year-over-year, from $130K to $0 in fiscal year 2025.
Is CNBX Pharms profitable?
No, CNBX Pharms (CNBX) reported a net income of -$314K in fiscal year 2025.
What is CNBX Pharms's earnings per share (EPS)?
CNBX Pharms (CNBX) reported diluted earnings per share of $0.00 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is CNBX Pharms's EBITDA?
CNBX Pharms (CNBX) had EBITDA of -$272K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is CNBX Pharms's operating cash flow?
CNBX Pharms (CNBX) generated -$171K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are CNBX Pharms's total assets?
CNBX Pharms (CNBX) had $18K in total assets as of fiscal year 2025, including both current and long-term assets.
How many shares does CNBX Pharms have outstanding?
CNBX Pharms (CNBX) had 554M shares outstanding as of fiscal year 2025.
What is CNBX Pharms's current ratio?
CNBX Pharms (CNBX) had a current ratio of 0.01 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is CNBX Pharms's debt-to-equity ratio?
CNBX Pharms (CNBX) had a debt-to-equity ratio of -1.01 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is CNBX Pharms's return on assets (ROA)?
CNBX Pharms (CNBX) had a return on assets of -1703.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is CNBX Pharms's cash runway?
Based on fiscal year 2025 data, CNBX Pharms (CNBX) had $15K in cash against an annual operating cash burn of $171K. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is CNBX Pharms's debt-to-equity ratio negative or unusual?
CNBX Pharms (CNBX) has negative shareholder equity of -$2.5M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is CNBX Pharms's Piotroski F-Score?
CNBX Pharms (CNBX) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are CNBX Pharms's earnings high quality?
CNBX Pharms (CNBX) has an earnings quality ratio of 0.55x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can CNBX Pharms cover its interest payments?
CNBX Pharms (CNBX) has an interest coverage ratio of -5.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.